Lilly invests in epigenetic reprogramming biotech
NewLimit adds $45m in new funding at a $1.6bn valuation following preclinical progress that brings clinical trials closer…
Life Bio: epigenetic rejuvenation ‘transcends organs’
Longevity biotech presents data demonstrating therapeutic impact of partial epigenetic reprogramming across multiple biological systems. Today at the…